Skip to contentP
Protagenic Therapeutics, Inc.\new
P
PTIXProtagenic Therapeutics, Inc.\new Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2019 on file Net Income-$436.68K-$436.68KderivedN/M vs Q4 2019 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR
Operating Incomederived-$449,916N/M Operating Cash Flowderived-$320,868N/M ended Dec 31, 2020 · filed Mar 25, 2021 · 84 d after period end